ストックスクリーナーアプリを入手
1.69
1.74%
-0.03
アフターアワーズ：
1.75
0.06
+3.55%
前日終値:
$1.72
開ける：
$1.7
24時間の取引高:
59,776
Relative Volume:
0.04
時価総額：
$132.45M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-6.63%
1か月 パフォーマンス:
+9.74%
6か月 パフォーマンス:
+35.20%
1年 パフォーマンス:
-24.89%
1日の値動き範囲:
$1.66
$1.76
1週間の範囲:
$1.62
$1.87
52週間の値動き範囲:
$0.5506
$6.19
Citius Oncology Inc Stock (CTOR) Company Profile
CTOR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
1.69 | 134.80M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
154.11 | 67.83B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.00 | 46.74B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.65 | 43.52B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.86 | 20.12B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
313.13 | 14.11B | 2.99B | 1.21B | 1.13B | 25.06 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-27 | 開始されました | Maxim Group | Buy |
Citius Oncology Inc (CTOR) 最新ニュース
Is Citius Oncology Inc. exposed to currency risks2025 Volume Leaders & Reliable Momentum Entry Alerts - sundaytimes.kr
Is Citius Oncology Inc. showing insider buyingWeekly Investment Summary & Fast Entry Momentum Trade Alerts - thegnnews.com
Citius Pharmaceuticals shares fall 3.85% intraday after reporting fiscal third quarter results and raising $12.5 million in financings. - AInvest
Citius Oncology Inc. stock chart pattern explained2025 Breakouts & Breakdowns & Smart Allocation Stock Tips - Newser
Identifying reversal signals in Citius Oncology Inc.Earnings Trend Report & Real-Time Market Sentiment Alerts - Newser
Citius Oncology Beats Fiscal Q3 EPS - AOL.com
Citius Oncology Beats Q3 EPS Estimates with $0 Revenue - AInvest
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update - The Malaysian Reserve
Citius Oncology (CTOR) $9M Offering; Cash Runway Through Sept 2025 | TENKU SEC FilingForm 10-Q - Stock Titan
Citius Secures $21.5M Funding as Cancer Drug LYMPHIR Nears Q4 2025 Commercial Launch - Stock Titan
Risk adjusted return profile for Citius Oncology Inc. analyzedPrice Forecast Based on AI Analysis - Newser
Citius Oncology Announces Pricing of $9.0 Million Public Offering - ADVFN Brasil
Smart tools for monitoring Citius Oncology Inc.’s price actionHigh Yield Signals with Entry Timing - Newser
Citius Oncology Inc. stock trend outlook and recovery pathStrategy Chart for Real-Time Trade Flow - Newser
Chart overlay techniques for tracking Citius Oncology Inc.Free Capital Protection Trading Strategies - Newser
Is Now a Good Time to Reenter Citius Oncology Inc.Watchlist for Low Risk High Return Stocks Updated - beatles.ru
Citius Oncology IncAnticipates Commercial Launch of Lymphir in 2025 - 富途牛牛
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators - Benzinga
What analysts say about Citius Oncology Inc. stockMaximize gains with proven stock analysis - Jammu Links News
What institutional investors are buying Citius Oncology Inc. stockInvest smarter with expert stock recommendations - Jammu Links News
What is the risk reward ratio of investing in Citius Oncology Inc. stockUnlock exclusive trading strategies for gains - Jammu Links News
How volatile is Citius Oncology Inc. stock compared to the marketGet professional advice for portfolio optimization - Jammu Links News
Does Citius Oncology Inc. stock perform well during market downturnsUnlock real-time stock alerts for quick profits - Jammu Links News
How strong is Citius Oncology Inc. company’s balance sheetSkyrocketing returns - Jammu Links News
What are the latest earnings results for Citius Oncology Inc.Free Stock Market Trend Analysis - Jammu Links News
Why is Citius Oncology Inc. stock attracting strong analyst attentionAchieve breakthrough investment performance - Jammu Links News
What is Citius Oncology Inc. company’s growth strategyBuild a portfolio for long-term financial success - Jammu Links News
Should I hold or sell Citius Oncology Inc. stock in 2025Capitalize on market trends early - Jammu Links News
What drives Citius Oncology Inc. stock priceGet timely market insights for better trades - Jammu Links News
What are analysts’ price targets for Citius Oncology Inc. in the next 12 monthsFree Daily Trading Room Entry - Jammu Links News
How does Citius Oncology Inc. compare to its industry peersBreakthrough stock performance - Jammu Links News
How does Citius Oncology Inc. generate profit in a changing economyPost Market Target Finder To Watch Now - Jammu Links News
What makes Citius Oncology Inc. stock attractive to long term investorsPortfolio Diversification Stock Ideas From Experts - metal.it
Published on: 2025-07-29 19:38:23 - metal.it
Trendline Breach Raises Concern for Citius Oncology Inc. InvestorsFundamental + Technical Hybrid Stock Tips Shared - metal.it
Relative strength of Citius Oncology Inc. in sector analysisFundamental Analysis for Value Stock Selection - Newser
Citius Oncology Inc (CTOR) 財務データ
Citius Oncology Inc (CTOR) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
2.80%
0.22%
大文字化:
|
ボリューム (24 時間):